ArticleGigaScience2026
Epitope Generation Gateway: A biological context-dependent approach to cancer vaccine development.
Article in GigaScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPersonalized neoantigen discovery requires tools that not only identify putative epitopes but also prioritize candidates using biological features relevant to tumor fitness and immune escape. Here, we present Epitope Generation Gateway (EGG), a containerized pipeline that streamlines discovery and prioritization across variant types and human leukocyte antigen (HLA) contexts. EGG coordinates established components, Mutect2 for somatic single nucleotide variations (SNVs) and indels, STAR-Fusion for fusion events, ArcasHLA for HLA typing, and pVACtools for epitope sequence prediction, then augments peptide-level scores with biological context. For each patient, EGG builds co-expression and protein-protein interaction networks, uses centrality measures and CRISPR dependency data (DepMap) to flag genes important for tumor fitness, and annotates source genes with gene ontology terms, Hallmarks of Cancer processes, and IntOGen driver status.
resultsThis multi-layer information supports ranking of candidates that are predicted to be presented and that arise from genes essential to tumor fitness or embedded in key pathways, providing a framework to nominate epitopes whose source genes may be less dispensable under immune pressure. As a case study, we applied EGG to 30 TCGA skin cutaneous melanoma patients, demonstrating end-to-end execution and producing prioritized epitopes that emphasize peptides and alterations in high-centrality, dependency-supported essential genes.
conclusionsOverall, EGG links epitope prioritization to tumor systems biology and evolutionary rationale, prioritizing biologically contextualized cancer vaccine candidates from SNVs, indels, fusions, and splicing-derived epitopes while streamlining dataset analysis. EGG is available from GitHub at https://github.com/fhaive/epitope_generation_gateway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.